ストックスクリーナーアプリを入手
2.69
10.03%
-0.30
アフターアワーズ：
2.66
-0.03
-1.12%
前日終値:
$2.99
開ける：
$3.13
24時間の取引高:
5.01M
Relative Volume:
7.43
時価総額：
$32.53M
収益：
-
当期純損益:
$-30.15M
株価収益率:
-0.6725
EPS:
-4
ネットキャッシュフロー:
$-21.66M
1週間 パフォーマンス:
+78.15%
1か月 パフォーマンス:
+113.49%
6か月 パフォーマンス:
+4.26%
1年 パフォーマンス:
-44.54%
1日の値動き範囲:
$2.60
$3.74
1週間の範囲:
$1.43
$3.74
52週間の値動き範囲:
$1.10
$7.333
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
NRXP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.69 | 32.53M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nrx Pharmaceuticals Inc (NRXP) 最新ニュース
HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Subsidiary, Will Host an Investor Workshop for Qualified Institutional Investors at the Mar-A-Lago Club During the Week of January 6, 2025 - PR Newswire
HOPE Therapeutics Plans $100M Revenue Mental Health Clinic Acquisition Strategy at Mar-a-Lago Workshop - StockTitan
Acquisition of Kadima Neuropsychiatry Institute for CNS & - openPR
NRx Pharma unit to acquire psychiatric facility Kadima - MSN
NRx Pharmaceuticals Stock Rises 33% on Psychiatry Clinic Acquisition - MarketWatch
NRx Pharmaceuticals Announces Agreement with LifeSci Associates to Provide Financial Services and Support - GuruFocus.com
NRx Pharma to buy Kadima psychiatric clinic (NRXP:NASDAQ) - Seeking Alpha
Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics - PR Newswire
Walt Disney Company (DIS-N) QuotePress Release - The Globe and Mail
Crowdstrike Holdings Inc (CRWD-Q) QuotePress Release - The Globe and Mail
New Drug Application to the FDA for the Treatment of Suicidal - openPR
NRx Pharmaceuticals Takes Bold Step Toward FDA Approval for NRX-100 in Treatment of Suicidal Depression - Tandav Media
Best Momentum Stocks to Buy for December 30th - Yahoo Finance
NRx Pharmaceuticals seeks FDA nod for suicidal depression drug - Investing.com India
NRx Pharmaceuticals seeks FDA nod for suicidal depression drug By Investing.com - Investing.com Nigeria
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression - StreetInsider.com
NRx Pharma Advances FDA Application for Groundbreaking Ketamine Depression Treatment - StockTitan
New Strong Buy Stocks for December 24th - MSN
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024 - The Eastern Progress Online
NRX Pharmaceuticals chairman Jonathan Javitt buys $46,800 in stock By Investing.com - Investing.com Canada
NRX Pharmaceuticals chairman Jonathan Javitt buys $46,800 in stock - Investing.com India
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic - Kilgore News Herald
Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics - The Eastern Progress Online
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024 - The Eastern Progress Online
Caterpillar Inc (CAT-N) QuotePress Release - The Globe and Mail
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024 - The Eastern Progress Online
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials" - The Eastern Progress Online
Ascendiant Capital Markets Issues Positive Forecast for NRx Pharmaceuticals (NASDAQ:NRXP) Stock Price - Defense World
NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on - GuruFocus.com
NRx Pharmaceuticals (NRXP) Upgraded to Buy: Here's Why - MSN
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter - GuruFocus.com
NRx Pharmaceuticals CEO to Present at NobleCon20 Emerging Growth Conference - StockTitan
NRx Pharmaceuticals reiterates shares target with Buy rating on Q3 report - Investing.com Nigeria
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper - GuruFocus.com
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Po - GuruFocus.com
Earnings call: NRx Pharmaceuticals projects profitability by 2025 - Investing.com Canada
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer - The Malaysian Reserve
NRX Pharmaceuticals Strengthens Leadership with New CFO Appointment - TipRanks
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2024 Earnings Call Transcript - Insider Monkey
NRx Pharmaceuticals Reports Progress in Drug Development - TipRanks
NRx Pharmaceuticals names Michael Abrams as new CFO - Investing.com
NRx Pharmaceuticals, Inc. Announces Chief Financial Officer Changes - Marketscreener.com
NRXPNRX Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
NRX Pharmaceuticals Inc (NRXP) Quarterly 10-Q Report - Quartzy
NRX Pharmaceuticals Advances in Mental Health Sector - TipRanks
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update - PR Newswire
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
NRx Pharmaceuticals delays Q3 results call to November 18 By Investing.com - Investing.com Canada
Nrx Pharmaceuticals Inc (NRXP) 財務データ
収益
当期純利益
現金流量
EPS
0.60%
2.24%
大文字化:
|
ボリューム (24 時間):